About the Company
We do not have any company description for bioAffinity Technologies, Inc. at the moment.
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological Research
Employees
1
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on bioAffinity Technologies, Inc.
bioAffinity Technologies Appoints New Members to Board of Directors
SAN ANTONIO, Texas, August 18, 2025--bioAffinity Technologies appoints leaders in corporate finance and the diagnosis and ...
bioAffinity Technologies Secures $1.2M Through Private Placement
Affinity Technologies, Inc. ( (BIAF) ) just unveiled an announcement. On August 13, 2025, bioAffinity Technologies, Inc. entered into a securities purchase agreement with institutional and accredited ...
bioAffinity Technologies, Inc. Announces Closing of $7.8 Million ...
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment.
bioAffinity Technologies Sees Surge in CyPath® Lung Test Sales
Affinity Technologies, Inc. ( ($BIAF) ) has issued an update. On August 13, 2025, bioAffinity Technologies announced a significant increase in ...
bioAffinity Technologies Announces Pricing of $2.66 Million Registered ...
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (BIAF) (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage ...
BIAFW bioAffinity Technologies, Inc. C/WTS 12/08/27 (TO PUR COM)
bioAffinity Technologies, Inc. C/WTS 12/08/27 (TO PUR COM) SEC Filing - Securities Registration Statement (S-1) November 27, 2024 SEC FilingsWed, Nov. 27, 2024 ...
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
SAN ANTONIO, August 13, 2025--bioAffinity Technologies reports a significant surge in commercial sales of CyPath® Lung with ...
bioAffinity Technologies Announces Closing of Warrant Inducement ...
bioAffinity Technologies, Inc. announced today it has closed its previously announced warrant exercise agreements with four existing accredited investors to exercise certain outstanding warrants ...
bioAffinity Technologies, Inc. Announces Closing of $7.8 Million ...
bioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public Offering September 06, 2022 11:28 AM Eastern Daylight Time ...
bioAffinity Technologies Announces Pricing of $2.66 Million ... - Nasdaq
bioAffinity Technologies, Inc., a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has entered into a securities purchase ...
Similar Companies
Loading the latest forecasts...